Leonard Schleifer (#1592)
Most people, they lose their edge. We just push the edge further forward.
- $ 3 B
- Pharmaceuticals
- United States
- M
- 73 Years
Rest in Peace Ask Jeeves, every search comes to an end
County commissioners call on lawmakers to up funding for 911 dispatch systems
Spirit Airlines Is Going Out Of Business; Effective IMMEDIATELY
Pokémon Scalpers Selling Limited-Edition Pop-Tarts For Ridiculous Prices
Bennett says Netanyahu gov't 'boycotting' West Bank settlements amid Carrefour subsidy deal
Golf gear on sale now: Up to 65% off adidas, 45% off Puma, 15% off Mizuno, more
Families across the US can't find childcare — this map shows where it's worst
Median sales surge 61% in a Queens neighborhood that’s now the fifth priciest in NYC
Greg Brockman says his stake in OpenAI is worth nearly $30 billion
TeraWulf Announces Participation in Upcoming Investor and Industry Conferences
About Me
Leonard Schleifer cofounded drugmaker Regeneron in 1988, and remains CEO of the Tarrytown, New York-based company. Schleifer took Regeneron public in 1991; he owns 2% of the company's common stock. Sales of Regeneron's blockbuster drug Eylea, a treatment for macular degeneration, were $4.8 billion in the U.S. in 2024. Regeneron has developed 12 FDA-approved medicines.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Leonard Schleifer’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Leonard Schleifer’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $2.6B
(May 4, 2026)
© Iconic Billionaires